Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Verona Pharma plc VRNA
$21.31
-$0.65 (-3.05%)
На 18:01, 12 мая 2023
+34.21%
Потенциал через год
Ранг: 3
Ключевые показатели
-
Marketcap
1727469660.00000000
-
week52high
26.44
-
week52low
3.41
-
Revenue
458000
-
P/E TTM
-19
-
Beta
0.18304400
-
EPS
-1.06000000
-
Last Dividend
0.00000000
-
Next Earnings Date
09 мая 2023 г. в 10:59
Описание компании
Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis. It is developing ensifentrine in three formulations, including nebulizer, dry powder inhaler, and pressurized metered-dose inhaler. Verona Pharma plc was incorporated in 2005 and is headquartered in London, the United Kingdom.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Wedbush | Outperform | Outperform | 17 июн 2022 г. |
| Canaccord Genuity | Buy | Buy | 12 ноя 2021 г. |
| HC Wainwright & Co. | Buy | 13 сент 2021 г. | |
| Canaccord Genuity | Buy | Buy | 03 мая 2021 г. |
| Canaccord Genuity | Buy | 10 авг 2020 г. | |
| HC Wainwright & Co. | Buy | Buy | 29 авг 2022 г. |
| Piper Sandler | Overweight | 26 авг 2022 г. | |
| HC Wainwright & Co. | Buy | Buy | 21 дек 2022 г. |
| Truist Securities | Buy | Buy | 20 дек 2022 г. |
| BTIG | Buy | Buy | 20 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Rickard Kathleen A. | D | 3077312 | 28752 | 02 февр 2023 г. |
| Hahn Mark W | D | 16432312 | 413168 | 01 февр 2023 г. |
| Poll Claire | D | 774256 | 152000 | 01 февр 2023 г. |
| Poll Claire | A | 926256 | 152000 | 01 февр 2023 г. |
| Poll Claire | D | 2059439 | 152000 | 01 февр 2023 г. |
| ZACCARDELLI DAVID | D | 17342872 | 432928 | 01 февр 2023 г. |
| Rickard Kathleen A. | D | 3106064 | 89960 | 01 февр 2023 г. |
| Poll Claire | D | 8328 | 58280 | 20 янв 2023 г. |
| Poll Claire | D | 0 | 34248 | 20 янв 2023 г. |
| Poll Claire | A | 2211439 | 178800 | 20 янв 2023 г. |
Новостная лента
Verona Pharma to Present Expanded Analyses of Positive Phase 3 ENHANCE Studies in COPD in Multiple Presentations at ATS 2023
GlobeNewsWire
02 мая 2023 г. в 02:00
12 Abstracts and one Symposium further support potential of ensifentrine, a first-in-class, selective, dual inhibitor of PDE3 and PDE4
Verona Pharma to Report First Quarter 2023 Financial Results and Provide Corporate Update
GlobeNewsWire
25 апр 2023 г. в 02:00
LONDON and RALEIGH, N.C., April 25, 2023 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces that it will report its financial results for the first quarter ended March 31, 2023 on Tuesday, May 9, 2023 and host an investment community conference call at 9:00 a.m. EDT / 2:00 p.m. BST to discuss these financial results and provide a corporate update.
Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air
Seeking Alpha
16 апр 2023 г. в 01:22
Verona Pharma: Ensifentrine Vs. Dupixent, Ensifentrine Is A Breath Of Fresh Air
Tech Stocks Are Surging
InvestorPlace
31 мар 2023 г. в 21:02
The Nasdaq 100 is on a tear
Verona's Ensifentrine: A Promising Novel Treatment For COPD Patients
Seeking Alpha
27 мар 2023 г. в 02:31
Verona Pharma's ensifentrine is a first-in-class, inhaled, dual inhibitor of the enzymes PDE3 and PDE4, targeting both bronchodilation and inflammation. Positive Phase 3 results from the ENHANCE trials show significant improvements in lung function, symptoms, and quality of life for COPD patients.